Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Trial Profile

An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Bladder cancer; Solid tumours; Ureteral neoplasms; Urogenital cancer
  • Focus Adverse reactions; Registrational
  • Acronyms STRONG
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Feb 2018 According to trial design and details for module A (urothelial and non-urothelial urinary tract carcinoma) presented at the 2018 Genitourinary Cancers Symposium, this study is expected to be completed within 5 years.
    • 16 Feb 2018 Trial design and details for module A (urothelial and non-urothelial urinary tract carcinoma), presented at the 2018 Genitourinary Cancers Symposium.
    • 08 Jan 2018 Planned End Date changed from 29 Apr 2022 to 26 Mar 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top